Results 1 to 10 of about 777 (156)

Sulbactam–Durlobactam: A Novel Antibiotic Combination for the Treatment of Acinetobacter baumannii –Calcoaceticus Complex (ABC) Hospital‐Acquired Bacterial Pneumonia and Ventilator‐Associated Bacterial Pneumonia [PDF]

Canadian Journal of Infectious Diseases and Medical Microbiology
Summary: Sulbactam–durlobactam is a recently approved antimicrobial combination of two β-lactamase inhibitors for the treatment of hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP) associated with ...
Wissam K Kabbara, Hanine Mansour
exaly   +4 more sources

Pharmacokinetic and pharmacodynamic evaluation of sulbactam‐durlobactam in a critically ill patient on continuous venovenous hemofiltration infected with carbapenem‐resistant Acinetobacter baumannii‐calcoaceticus complex [PDF]

Pharmacotherapy
Background: Drug databases currently do not provide dosing guidance for sulbactam-durlobactam in continuous renal replacement therapy. Herein, we present the first in vivo pharmacokinetic (PK) evaluation of sulbactam-durlobactam during continuous ...
, Aliaa Fouad, Hanna F Roenfanz
exaly   +5 more sources

Acinetobacter baumannii Resistance to Sulbactam/Durlobactam: A Systematic Review [PDF]

Antibiotics, 2022
Infections caused by carbapenem-resistant Acinetobacter baumannii (CRAB) have limited therapeutic options. Sulbactam-durlobactam is a combination of two βlactamase inhibitors with activity against CRAB under phase 3 clinical investigation. We performed a
Luigi Principe, Stefano Di Bella, Jacopo Conti, Mariagrazia Perilli, Alessandra Piccirilli, Cristina Mussini, Giuliana Decorti   +6 more
doaj   +6 more sources

Sulbactam-durlobactam combination therapy for carbapenem-resistant Acinetobacter baumannii sepsis with cutaneous involvement in an infant with acute monocytic leukemia: A case report [PDF]

Frontiers in Pharmacology
Carbapenem-resistant Acinetobacter baumannii (CRAb) causes severe infections and poses significant treatment challenges. Sulbactam-durlobactam (SUL-DUR) is a novel antibiotic, but its use in children and infants has not been reported.
Chunxi Fu, Chunxi Fu, Xue Tang, Xue Tang, Xia Guo, Xia Guo, Liang Huang, Liang Huang, Liang Huang, Ju Gao, Ju Gao, Rong Yang, Rong Yang   +12 more
doaj   +4 more sources

An overview of sulbactam‐durlobactam approval and implications in advancing therapeutics for hospital‐acquired and ventilator‐associated pneumonia by acinetobacter baumannii‐calcoaceticus complex: A narrative review [PDF]

Health Science Reports
Purpose Infections caused by Acinetobacter baumannii, particularly those resistant to antibiotics such as carbapenem, have become a global health crisis with a significant mortality rate.
Ayush Anand, Amogh Verma, Sarabjeet Kaur, Priyangi Kathayat, Rachel M. Manoj, Aakanksha Aakanksha, Justice K. Turzin, Prakasini Satapathy, Mahalaqua N. Khatib, Shilpa Gaidhane, Quazi S. Zahiruddin, Neelima Kukreti, Sarvesh Rustagi, Arihant Surana   +13 more
doaj   +3 more sources

Case report: Successful treatment of OXA-23 Acinetobacter baumannii neurosurgical infection and meningitis with sulbactam-durlobactam combination therapy [PDF]

Frontiers in Medicine
Meningitis caused by Acinetobacter species is a rare complication of neurosurgical procedures, although it is associated with high morbidity and mortality.
Nicholas J Mercuro
exaly   +4 more sources

Cefiderocol and Sulbactam-Durlobactam against Carbapenem-Resistant Acinetobacter baumannii [PDF]

Antibiotics, 2023
Infections caused by carbapenem-resistant Acinetobacter baumannii (CRAB) remain a clinical challenge due to limited treatment options. Recently, cefiderocol, a novel siderophore cephalosporin, and sulbactam-durlobactam, a bactericidal β-lactam–β ...
Arta Karruli, Antonella Migliaccio, Spyros Pournaras, Emanuele Durante-Mangoni, Raffaele Zarrilli   +4 more
doaj   +2 more sources

A randomized, double‐blind, placebo‐ and positive‐controlled crossover study of the effects of durlobactam on cardiac repolarization in healthy subjects

Clinical and Translational Science, 2021
Durlobactam (formerly ETX2514) is a diazabicyclooctane β‐lactamase inhibitor that inhibits class A, C, and D β‐lactamases. Sulbactam combined with durlobactam has in vitro and in vivo activity against Acinetobacter baumannii including carbapenem‐ and ...
John O’Donnell, Kathleen Maloney, Melissa Steidler, Royce Morrison, Robin Isaacs   +4 more
doaj   +2 more sources

Durlobactam, a New Diazabicyclooctane β-Lactamase Inhibitor for the Treatment of Acinetobacter Infections in Combination With Sulbactam

Frontiers in Microbiology, 2021
Durlobactam is a new member of the diazabicyclooctane class of β-lactamase inhibitors with broad spectrum activity against Ambler class A, C, and D serine β-lactamases.
Adam B Shapiro, Samir H Moussa, Sarah M McLeod   +2 more
exaly   +3 more sources

Sulbactam–Durlobactam for Carbapenem-Resistant Acinetobacter baumannii–calcoaceticus Complex [PDF]

Pathogens
Carbapenem-resistant Acinetobacter baumannii infections pose a significant challenge due to their severity and the poor prognoses they often result in, particularly in cases where there are risk factors present. The United States (US) Centers for Disease
Francesco Nappi
doaj   +2 more sources